Nuvation Bio Inc. (NUVB): Price and Financial Metrics


Nuvation Bio Inc. (NUVB): $2.42

-0.01 (-0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NUVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NUVB Stock Price Chart Interactive Chart >

Price chart for NUVB

NUVB Price/Volume Stats

Current price $2.42 52-week high $6.23
Prev. close $2.43 52-week low $1.59
Day low $2.41 Volume 390,225
Day high $2.55 Avg. volume 700,913
50-day MA $2.00 Dividend yield N/A
200-day MA $2.91 Market Cap 528.51M

Nuvation Bio Inc. (NUVB) Company Bio


Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.


NUVB Latest News Stream


Event/Time News Detail
Loading, please wait...

NUVB Latest Social Stream


Loading social stream, please wait...

View Full NUVB Social Stream

Latest NUVB News From Around the Web

Below are the latest news stories about NUVATION BIO INC that investors may wish to consider to help them evaluate NUVB as an investment opportunity.

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

NEW YORK, December 19, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib.

Yahoo | December 19, 2022

Trade Alert: The Independent Director Of Nuvation Bio Inc. (NYSE:NUVB), Kathryn Falberg, Has Just Spent US$484k Buying A Few More Shares

Potential Nuvation Bio Inc. ( NYSE:NUVB ) shareholders may wish to note that the Independent Director, Kathryn Falberg...

Yahoo | December 7, 2022

H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nuvation Bio (NUVB - Research Report) today and set a price target of $4.50. The company's shares closed last Friday at $2.09.According to TipRanks, Burns is an analyst with an average return of -22.7% and a 22.60% success rate. Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE.Nuvation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $10.45 and a one-year low of $1.92. Currently, Nuvation Bio has an average volume of 616.3K.

Carrie Williams on TipRanks | November 7, 2022

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK, November 03, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.

Yahoo | November 3, 2022

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce

Yahoo | August 11, 2022

Read More 'NUVB' Stories Here

NUVB Price Returns

1-mo 38.29%
3-mo 9.01%
6-mo -12.32%
1-year -57.24%
3-year N/A
5-year N/A
YTD 26.04%
2022 -77.41%
2021 -27.35%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6764 seconds.